

# Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

NCT07036003

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Dr. David Wasserstein
Enrollment	34 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Between 18 - 65 years old.
- Diagnosis of isolated knee osteoarthritis for greater than 6 months.

### Exclusion (13)

- Previous or pending major intra-articular or reconstructive surgery to the involved knee, including femoral/tibial osteotomies, ligament repair/reconstruction, or cartilage transplantation. Patients with remote (>1 year) diagnostic arthroscopy, arthroscopic debridement, meniscectomy, or meniscal repair may be allowed to participate at the investigators' discretion.
- Previous major trauma (including fracture, dislocation, open injury) to the involved knee, or ipsilateral hip, knee, ankle, or hip. Patients with prior complete ligament tears will be excluded, patients with chronic partial thickness ligament tears or degenerative/complex meniscal tears (>6 months from injury) may be included at the investigators' discretion
- Recent (less than 6 months) intra-articular injection into the involved knee.
- High grade ligamentous knee injury.
- Known allergy to recombinant human growth hormone (rHGH) or reconstitutive solutions.

... and 8 more (see full listing online)

## Locations (1 total)

---

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada